PMID- 22561335
OWN - NLM
STAT- MEDLINE
DCOM- 20121112
LR  - 20220316
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 17
IP  - 6
DP  - 2012
TI  - Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant 
      taxane-containing chemotherapy sensitivity in locally advanced breast cancer.
PG  - 792-800
LID - 10.1634/theoncologist.2011-0381 [doi]
AB  - PURPOSE: Aneusomy 17 causes inconsistency in fluorescence in situ hybridization 
      (FISH)-based human epidermal growth factor receptor (HER)-2 status assessment 
      using different algorithms (copy number or the HER-2/centromere enumerator probe 
      17 [CEP-17] ratio). We investigated the effects of FISH-based HER-2 status 
      assessment and aneusomy 17 on responsiveness to neoadjuvant chemotherapy (NAC). 
      PATIENTS AND METHODS: This prospective study recruited 152 patients with locally 
      advanced breast cancer who underwent four-cycle weekly paclitaxel plus 
      carboplatin without trastuzumab. RESULTS: The pathologic complete remission (pCR) 
      rate in the breast and axilla was 24.3% (95% confidence interval [CI], 
      17.7%-32.0%). Although HER-2 status, assessed by either HER-2/CEP-17 ratio-based 
      FISH or copy number-based FISH, was a predictor of NAC sensitivity, 
      ratio-assessed HER-2 status had a poorer performance in determining patients' 
      responsiveness to NAC (p = .029). Patients who were not HER-2 amplified when 
      assessed using the HER-2/CEP-17 ratio but were HER-2 amplified when assessed 
      using copy number (~5%) were eventually proven to be responsive to NAC, with a 
      pCR rate of 57% (95% CI, 18.4%-90.1%). In contrast, patients who were HER-2 
      amplified when assessed by the ratio but not HER-2 amplified when assessed using 
      copy number (~3%) were completely irresponsive. Higher HER-2 copy numbers 
      represented increasing chances of a pCR (adjusted odds ratio, 3.09; 95% CI, 
      1.35-7.08), with an apparent gene-dose effect (p for trend < .001). CONCLUSION: 
      It is likely that HER-2 copy number but not the HER-2/CEP-17 ratio determines NAC 
      sensitivity. Additional studies to validate our findings are warranted.
FAU - Yu, Ke-Da
AU  - Yu KD
AD  - Department of Breast Surgery, Cancer Center and Cancer Institute, Fudan 
      University, 399 Ling-Ling Road, Shanghai, P.R. China.
FAU - Liu, Guang-Yu
AU  - Liu GY
FAU - Zhou, Xiao-Yan
AU  - Zhou XY
FAU - Zhou, Ying
AU  - Zhou Y
FAU - Wu, Jiong
AU  - Wu J
FAU - Chen, Can-Ming
AU  - Chen CM
FAU - Shen, Zhen-Zhou
AU  - Shen ZZ
FAU - Shao, Zhi-Ming
AU  - Shao ZM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120504
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Taxoids)
RN  - 1605-68-1 (taxane)
RN  - BG3F62OND5 (Carboplatin)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Antineoplastic Agents/*therapeutic use
MH  - Axilla/pathology
MH  - Breast Neoplasms/*drug therapy/*genetics/pathology
MH  - Bridged-Ring Compounds/*therapeutic use
MH  - Carboplatin/therapeutic use
MH  - *Chromosomes, Human, Pair 17
MH  - Female
MH  - Gene Dosage
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Logistic Models
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Paclitaxel/therapeutic use
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Taxoids/*therapeutic use
MH  - Young Adult
PMC - PMC3380878
COIS- Disclosures: The authors indicated no financial relationships. Section Editors: 
      Gabriel Hortobagyi: Allergan, Genentech, sanofi-aventis, Novartis (C/A); Novartis 
      (RF); Kathleen Pritchard: Novartis, Roche, AstraZeneca, Pfizer, Abraxis, 
      Boehringer-Ingelheim (C/A), (RF) Reviewer "A" : Genentech (C/A); Novartis, 
      GlaxoSmithKline (RF) Reviewer "B": WntResearch Inc. (E); TIMP-1 as biomarker 
      (IP); DAKO A/S, Exiqon A/S, WntResearch (C/A), The Danish Cancer Society, The 
      Danish Strategic Research (RF); Exiqon A/S (O) Reviewer "C": Roche International 
      (C/A); Roche Canada (H), (RF) Reviewer "D": None
EDAT- 2012/05/09 06:00
MHDA- 2012/11/13 06:00
PMCR- 2013/06/01
CRDT- 2012/05/08 06:00
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/11/13 06:00 [medline]
PHST- 2013/06/01 00:00 [pmc-release]
AID - theoncologist.2011-0381 [pii]
AID - 3779434 [pii]
AID - 10.1634/theoncologist.2011-0381 [doi]
PST - ppublish
SO  - Oncologist. 2012;17(6):792-800. doi: 10.1634/theoncologist.2011-0381. Epub 2012 
      May 4.